

Supplemental Material




Fig. S1. VE against hospitalization by vaccine plotted against variant-specific reductions in neutralizing antibody titers relative to WT virus. Each point (and 95% CI) represents a single estimate of VE for a single vaccine & virus variant from an observational study. Points have been slightly jittered along the x-axis to facilitate presentation.




Fig. S2. VE against symptomatic disease by vaccine plotted against variant-specific reductions in neutralizing antibody titers relative to WT virus. Each point (and 95% CI) represents a single estimate of VE for a single vaccine & virus variant from an observational study. Points have been slightly jittered along the x-axis to facilitate presentation.




Fig. S3. Comparison of estimated VE for the Omicron variant and Delta variants for two endpoints, two vaccines, and two immune statuses (6+ months after two doses (Waned) and shortly after a 3rd dose (Boosted)).

Table S1: Inverse of neutralizing antibody titers relative to WT (1/NATR_{var}).

| Reference | Alpha | Gamma | Delta | Beta | BA.1 | BA.2 | BA.4/5 | BA.1 (Dec. 2021) |
|-----------|-------|-------|-------|------|------|------|--------|------------------|
| 1 | 1.1 | 1.2 | 0 | 4.2 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 | 0 | 19.3 | 14 | 23.3 | 0 |
| 3 | 0 | 0 | 0 | 7 | 32.3 | 0 | 0 | 0 |
| 4 | 1.5 | 4 | 0 | 2.5 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41.4 |
| 6 | 0 | 0 | 7.7 | 0 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 11.4 | 66.3 | 0 | 0 | 0 |
| 8 | 2.5 | 1.1 | 0 | 4.6 | 0 | 0 | 0 | 0 |
| 9 | 2.1 | 6.3 | 0 | 39.4 | 0 | 0 | 0 | 0 |
| 10 | 1.6 | 0 | 3.2 | 13.7 | 68.3 | 0 | 0 | 0 |
| 11 | 0 | 0 | 0 | 0 | 6.2 | 6.2 | 6.2 | 0 |
| 12 | 0 | 0 | 0 | 0 | 9.6 | 8.9 | 0 | 0 |
| 13 | 2.1 | 2.3 | 0 | 12.2 | 0 | 0 | 0 | 0 |
| 14 | 0.8 | 1.2 | 0 | 2.7 | 0 | 0 | 0 | 0 |
| 15 | 0 | 0 | 2 | 6.2 | 12.9 | 0 | 0 | 0 |
| 16 | 1.5 | 2 | 2.2 | 8.8 | 0 | 0 | 0 | 0 |

| | | | | | | | | |
|----|-----|-----|-----|------|-----|-----|------|----|
| 17 | 0 | 0 | 0 | 0 | 7.2 | 5.6 | 9.3 | 0 |
| 18 | 1.5 | 2.2 | 0 | 3.4 | 0 | 0 | 0 | 0 |
| 19 | 0 | 0 | 0 | 0 | 4.9 | 0 | 13.6 | 0 |
| 20 | 1.4 | 1.8 | 0 | 9.1 | 0 | 0 | 0 | 0 |
| 21 | 3.5 | 4.8 | 0 | 12.1 | 0 | 0 | 0 | 0 |
| 22 | 1.9 | 2.3 | 4.4 | 5.3 | 0 | 0 | 0 | 0 |
| 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 |
| 24 | 2 | 3.2 | 2.2 | 7.5 | 0 | 0 | 0 | 0 |
| 25 | 0 | 0 | 0 | 0 | 27 | 23 | 0 | 0 |
| 26 | 2.2 | 1.9 | 0 | 4.6 | 0 | 0 | 0 | 0 |

Table S2: The fitted model for $\ln(\text{NATR}_{\text{var}})$ with variant a fixed effect and study as a random effect. Alpha was the reference level; the standard deviation of the random effect, study, was 0.51.

| Predictor | Estimate | SE | t-value | P-value |
|-------------------|----------|------|---------|---------|
| Alpha (Intercept) | 0.45 | 0.16 | 2.75 | 0.0087 |
| Gamma | 0.32 | 0.16 | 2.05 | 0.048 |
| Delta | 0.37 | 0.23 | 1.63 | 0.11 |
| Beta | 1.37 | 0.15 | 9.26 | <0.001 |
| BA.1 | 2.47 | 0.22 | 11.06 | <0.001 |
| BA.2 | 2.17 | 0.29 | 7.49 | <0.001 |
| BA.4/5 | 2.54 | 0.31 | 8.25 | <0.001 |
| BA.1 Dec. 2021 | 3.22 | 0.49 | 6.63 | <0.001 |

Table S3: Estimates of fold reduction in neutralizing antibody titers for virus variants relative to WT (NATR_{var}) with 95% CIs.

| Variant | Fold Reduction (95% CI) |
|------------------|-------------------------|
| Alpha | 1.57 (1.14-2.16) |
| Gamma | 2.15 (1.55-2.99) |
| Delta | 2.27 (1.45-3.55) |
| Beta | 6.17 (4.58-8.30) |
| BA.1 | 18.5 (12.8-26.7) |
| BA.2 | 13.6 (8.3-22.4) |
| BA.4/5 | 19.9 (11.6-34.1) |
| BA.1 (Dec. 2021) | 39.1 (16.0-96.0) |

Table S4: Vaccine effectiveness against hospitalization estimates used to fit the VE-NATR_{tot} model and shown in Figure 2.

| Variant | Reference | Vaccine | VE | 95% CI | Effective cases vaccine group | Effective cases control group |
|---------|---------------|-----------------|-------|-----------|-------------------------------|-------------------------------|
| Alpha | ²⁷ | Ad26.COV2.S | 0.81 | 0.79-0.84 | 190 | 1000 |
| Alpha | ²⁸ | BNT162b2 | 0.96 | 0.83-0.99 | 1.9 | 46.9 |
| Alpha | ²⁹ | BNT162b2 | 0.979 | 0.91-1 | 2 | 94 |
| Alpha | ²⁹ | ChAdOx1 nCoV-19 | 0.939 | 0.85-0.98 | 5 | 81.6 |
| Alpha | ³⁰ | BNT162b2 | 0.95 | 0.78-0.99 | 1.8 | 36.6 |
| Alpha | ³⁰ | ChAdOx1 nCoV-19 | 0.86 | 0.53-0.96 | 3 | 21.3 |
| Alpha | ³¹ | BNT162b2 | 0.972 | 0.97-0.98 | 28 | 1000 |
| Alpha | ³² | BNT162b2 | 0.94 | 0.6-0.99 | 1.1 | 18.6 |
| Alpha | ³³ | BNT162b2 | 0.96 | 0.94-0.97 | 27.3 | 681.3 |
| Alpha | ³³ | mRNA-1273 | 0.95 | 0.92-0.97 | 17.8 | 356.3 |
| Alpha | ³³ | ChAdOx1 nCoV-19 | 0.92 | 0.41-0.99 | 1 | 12.9 |
| Beta | ³³ | BNT162b2 | 0.92 | 0.39-0.99 | 1 | 12.4 |
| Delta | ²⁷ | Ad26.COV2.S | 0.85 | 0.73-0.91 | 12.9 | 85.8 |
| Delta | ³⁴ | Ad26.COV2.S | 0.6 | 0.31-0.77 | 17.8 | 44.5 |
| Delta | ³⁴ | BNT162b2 | 0.8 | 0.73-0.85 | 52.2 | 261 |
| Delta | ³⁴ | mRNA-1273 | 0.95 | 0.92-0.97 | 17.4 | 347.5 |
| Delta | ²⁸ | BNT162b2 | 0.98 | 0.97-0.98 | 20 | 1000 |

| | | | | | | |
|-------|---------------|-----------------|-------|-----------|------|-------|
| Delta | ²⁸ | mRNA-1273 | 0.97 | 0.96-0.98 | 30 | 1000 |
| Delta | ²⁸ | ChAdOx1 nCoV-19 | 0.92 | 0.86-0.95 | 13.5 | 169.2 |
| Delta | ²⁹ | BNT162b2 | 0.967 | 0.96-0.97 | 33 | 1000 |
| Delta | ²⁹ | ChAdOx1 nCoV-19 | 0.93 | 0.92-0.94 | 70 | 1000 |
| Delta | ³⁵ | BNT162b2 | 0.93 | 0.84-0.96 | 6 | 85.8 |
| Delta | ³⁶ | BNT162b2 | 0.976 | 0.93-0.99 | 3.3 | 135.6 |
| Delta | ³⁰ | BNT162b2 | 0.96 | 0.86-0.99 | 2.6 | 65 |
| Delta | ³⁰ | ChAdOx1 nCoV-19 | 0.92 | 0.75-0.97 | 3 | 37.7 |
| Delta | ³³ | BNT162b2 | 0.98 | 0.96-0.99 | 8.2 | 410.4 |
| Delta | ³³ | mRNA-1273 | 0.98 | 0.93-1 | 2.5 | 123.6 |
| Delta | ³³ | ChAdOx1 nCoV-19 | 0.9 | 0.67-0.97 | 2.9 | 28.7 |
| Gamma | ²⁸ | BNT162b2 | 0.95 | 0.83-0.99 | 2.7 | 53.6 |
| Gamma | ³⁷ | Ad26.COV2.S | 0.729 | 0.35-0.91 | 6.2 | 23 |
| Gamma | ³³ | BNT162b2 | 0.94 | 0.59-0.99 | 1.1 | 18.3 |

Table S5: Vaccine effectiveness against symptomatic disease estimates used to fit the VE-NATR_{tot} model and shown in Figure 2.

| Variant | Reference | Vaccine | VE | 95% CI | Effective cases vaccine group | Effective cases control group |
|---------|---------------|----------|------|-----------|-------------------------------|-------------------------------|
| Alpha | ³¹ | BNT162b2 | 0.97 | 0.97-0.97 | 30 | 1000 |
| Alpha | ³² | BNT162b2 | 0.82 | 0.73-0.88 | 27.9 | 155.2 |
| Alpha | ³³ | BNT162b2 | 0.89 | 0.87-0.9 | 110 | 1000 |

| | | | | | | |
|-------|---------------|-----------------|-------|------------|-------|-------|
| Alpha | ³³ | mRNA-1273 | 0.92 | 0.88-0.95 | 24.7 | 308.2 |
| Alpha | ³³ | ChAdOx1 nCoV-19 | 0.91 | 0.62-0.98 | 2 | 22.4 |
| Alpha | ³⁸ | BNT162b2 | 0.937 | 0.92-0.95 | 49.7 | 788.2 |
| Alpha | ²⁹ | BNT162b2 | 0.95 | 0.94-0.96 | 50 | 1000 |
| Alpha | ³⁸ | ChAdOx1 nCoV-19 | 0.745 | 0.68-0.79 | 104.5 | 409.7 |
| Alpha | ³⁹ | NVX-CoV2373 | 0.83 | 0.71-0.94 | 14.1 | 82.7 |
| Alpha | ⁴⁰ | ChAdOx1 nCoV-19 | 0.7 | 0.44-0.85 | 12.6 | 42.1 |
| Beta | ³³ | BNT162b2 | 0.87 | 0.08-0.98 | 1.1 | 8.7 |
| Beta | ³³ | BNT162b2 | 1 | 0.54-1 | 0 | 17.8 |
| Beta | ⁴¹ | Ad26.COV2.S | 0.64 | 0.41-0.79 | 21 | 58.2 |
| Beta | ⁴² | NVX-CoV2373 | 0.51 | 0-0.76 | 11.2 | 22.9 |
| Beta | ⁴³ | ChAdOx1 nCoV-19 | 0.1 | -0.77-0.55 | 15.7 | 17.5 |
| D614G | ⁴¹ | Ad26.COV2.S | 0.66 | 0.55-0.75 | 62.2 | 182.9 |
| D614G | ⁴⁴ | ChAdOx1 nCoV-19 | 0.67 | 0.57-0.74 | 81.9 | 248.1 |
| D614G | ⁴⁵ | CoronaVac | 0.84 | 0.65-0.92 | 7.5 | 47 |
| D614G | ⁴⁶ | CoronaVac | 0.65 | 0.20-0.85 | 7.4 | 21.2 |
| D614G | ⁴⁷ | mRNA-1273 | 0.94 | 0.89-0.97 | 10.7 | 177.9 |
| D614G | ⁴⁸ | NVX-CoV2373 | 0.9 | 0.83-0.95 | 14.5 | 145.4 |
| D614G | ⁴⁹ | BNT162b2 | 0.95 | 0.90-0.98 | 8.2 | 164.2 |
| D614G | ⁵⁰ | Sputnik V | 0.92 | 0.86-0.95 | 13.9 | 173.5 |
| Delta | ³³ | BNT162b2 | 0.92 | 0.90-0.94 | 69.6 | 869.9 |

| | | | | | | |
|-------|---------------|-----------------|-------|-----------|-------|-------|
| Delta | ³³ | mRNA-1273 | 0.95 | 0.91-0.97 | 11.6 | 233 |
| Delta | ³³ | ChAdOx1 nCoV-19 | 0.87 | 0.69-0.95 | 5.8 | 44.5 |
| Delta | ³⁸ | BNT162b2 | 0.88 | 0.85-0.90 | 108.3 | 902.5 |
| Delta | ⁵¹ | BNT162b2 | 0.444 | 0.37-0.51 | 381 | 685 |
| Delta | ²⁹ | BNT162b2 | 0.835 | 0.83-0.84 | 165 | 1000 |
| Delta | ⁵² | BNT162b2 | 0.78 | 0.78-0.79 | 220 | 1000 |
| Delta | ⁵¹ | mRNA-1273 | 0.739 | 0.66-0.80 | 67.0 | 257 |
| Delta | ³⁸ | ChAdOx1 nCoV-19 | 0.67 | 0.61-0.72 | 201.2 | 609.8 |
| Gamma | ³³ | BNT162b2 | 0.88 | 0.73-0.94 | 6.4 | 53.3 |

Table S6: Predicted VE, 95% CIs and 95% PIs for two vaccines, two variants, two endpoints, and two immune statuses using the model shown in Figure 2.

| Variant | Prediction | Vaccine | Endpoint | Status | VE | 95% PI | 95% CI |
|---------|------------|-----------|---------------------|--------------------|------|------------|-----------|
| Omicron | Updated | mRNA-1273 | Hospitalization | Three-dose boosted | 0.9 | 0.82-0.95 | 0.89-0.91 |
| Omicron | Updated | BNT162b2 | Hospitalization | Three-dose boosted | 0.91 | 0.84-0.96 | 0.9-0.92 |
| Omicron | Updated | mRNA-1273 | Hospitalization | Two-dose waned | 0.56 | 0.37-0.71 | 0.48-0.64 |
| Omicron | Updated | BNT162b2 | Hospitalization | Two-dose waned | 0.46 | 0.25-0.63 | 0.37-0.56 |
| Omicron | Updated | mRNA-1273 | Symptomatic disease | Three-dose boosted | 0.69 | 0.56-0.8 | 0.67-0.72 |
| Omicron | Updated | BNT162b2 | Symptomatic disease | Three-dose boosted | 0.72 | 0.6-0.82 | 0.7-0.74 |
| Omicron | Updated | mRNA-1273 | Symptomatic disease | Two-dose waned | 0.24 | -0.01-0.43 | 0.18-0.3 |
| Omicron | Updated | BNT162b2 | Symptomatic disease | Two-dose waned | 0.18 | -0.09-0.38 | 0.13-0.24 |

| | | | | | | | |
|---------|--------------|-----------|---------------------|--------------------|------|------------|-----------|
| Omicron | Updated | mRNA-1273 | All infections | Three-dose boosted | 0.69 | 0.56-0.8 | 0.66-0.72 |
| Omicron | Updated | BNT162b2 | All infections | Three-dose boosted | 0.71 | 0.57-0.81 | 0.68-0.73 |
| Omicron | Updated | mRNA-1273 | All infections | Two-dose waned | 0.44 | 0.21-0.62 | 0.33-0.55 |
| Omicron | Updated | BNT162b2 | All infections | Two-dose waned | 0.38 | 0.14-0.59 | 0.27-0.52 |
| Omicron | Dec. 11 2021 | mRNA-1273 | Hospitalization | Three-dose boosted | 0.83 | 0.73-0.91 | 0.81-0.85 |
| Omicron | Dec. 11 2021 | BNT162b2 | Hospitalization | Three-dose boosted | 0.85 | 0.76-0.92 | 0.83-0.87 |
| Omicron | Dec. 11 2021 | mRNA-1273 | Hospitalization | Two-dose waned | 0.42 | 0.19-0.6 | 0.33-0.52 |
| Omicron | Dec. 11 2021 | BNT162b2 | Hospitalization | Two-dose waned | 0.33 | 0.08-0.53 | 0.24-0.44 |
| Omicron | Dec. 11 2021 | mRNA-1273 | Symptomatic disease | Three-dose boosted | 0.56 | 0.39-0.7 | 0.52-0.6 |
| Omicron | Dec. 11 2021 | BNT162b2 | Symptomatic disease | Three-dose boosted | 0.59 | 0.43-0.72 | 0.56-0.63 |
| Omicron | Dec. 11 2021 | mRNA-1273 | Symptomatic disease | Two-dose waned | 0.15 | -0.11-0.36 | 0.11-0.21 |
| Omicron | Dec. 11 2021 | BNT162b2 | Symptomatic disease | Two-dose waned | 0.11 | -0.17-0.32 | 0.07-0.16 |
| Omicron | Dec. 11 2021 | mRNA-1273 | All infections | Three-dose boosted | 0.62 | 0.46-0.75 | 0.57-0.67 |
| Omicron | Dec. 11 2021 | BNT162b2 | All infections | Three-dose boosted | 0.64 | 0.49-0.76 | 0.6-0.68 |
| Omicron | Dec. 11 2021 | mRNA-1273 | All infections | Two-dose waned | 0.36 | 0.12-0.57 | 0.24-0.51 |
| Omicron | Dec. 11 2021 | BNT162b2 | All infections | Two-dose waned | 0.31 | 0.06-0.54 | 0.2-0.47 |
| Delta | Delta | mRNA-1273 | Hospitalization | Three-dose boosted | 0.98 | 0.94-1 | 0.97-0.98 |
| Delta | Delta | BNT162b2 | Hospitalization | Three-dose boosted | 0.98 | 0.95-1 | 0.97-0.98 |
| Delta | Delta | mRNA-1273 | Hospitalization | Two-dose waned | 0.86 | 0.77-0.93 | 0.84-0.87 |
| Delta | Delta | BNT162b2 | Hospitalization | Two-dose waned | 0.81 | 0.7-0.89 | 0.78-0.83 |

| | | | | | | | |
|-------|-------|-----------|---------------------|--------------------|------|-----------|-----------|
| Delta | Delta | mRNA-1273 | Symptomatic disease | Three-dose boosted | 0.92 | 0.86-0.97 | 0.91-0.93 |
| Delta | Delta | BNT162b2 | Symptomatic disease | Three-dose boosted | 0.93 | 0.87-0.97 | 0.92-0.94 |
| Delta | Delta | mRNA-1273 | Symptomatic disease | Two-dose waned | 0.61 | 0.45-0.74 | 0.58-0.65 |
| Delta | Delta | BNT162b2 | Symptomatic disease | Two-dose waned | 0.52 | 0.33-0.66 | 0.47-0.56 |
| Delta | Delta | mRNA-1273 | All infections | Three-dose boosted | 0.84 | 0.74-0.92 | 0.8-0.88 |
| Delta | Delta | BNT162b2 | All infections | Three-dose boosted | 0.85 | 0.75-0.93 | 0.81-0.89 |
| Delta | Delta | mRNA-1273 | All infections | Two-dose waned | 0.65 | 0.5-0.77 | 0.61-0.69 |
| Delta | Delta | BNT162b2 | All infections | Two-dose waned | 0.6 | 0.43-0.73 | 0.54-0.66 |

Table S7: VE validation data for the Omicron variant shown in Figure 3 for two vaccines, two endpoints, and two immune statuses (two-dose waned and boosted with a third dose).

| Reference | Vaccine | Dose | Endpoint | VE | CI | Estimated cases vaccine group | Estimated cases control group |
|-----------|-----------|--------------------|-----------------|------|-------------|-------------------------------|-------------------------------|
| 53 | mRNA-1273 | Three-dose boosted | Hospitalization | 97.5 | 96.3 - 98.3 | 25.9 | 1037 |
| 54 | BNT162b2 | Two-dose waned | Hospitalization | 51.6 | 47.2 - 55.6 | 776.8 | 1604.9 |
| 54 | BNT162b2 | Three-dose boosted | Hospitalization | 88.8 | 87.3 - 90.1 | 273.1 | 2438.4 |
| 54 | mRNA-1273 | Three-dose boosted | Hospitalization | 90.2 | 87.3 - 92.5 | 60.7 | 618.9 |
| 55 | BNT162b2 | Two-dose waned | Hospitalization | 34.9 | 17.7 - 48.4 | 116.2 | 178.5 |

| | | | | | | | |
|----|-----------|--------------------|---------------------|------|-------------|---------|---------|
| 56 | BNT162b2 | Two-dose waned | Symptomatic disease | 8.8 | 7 - 10.5 | 20033.7 | 21966.8 |
| 56 | BNT162b2 | Three-dose boosted | Symptomatic disease | 67.2 | 66.5 - 67.8 | 12151 | 37045.9 |
| 56 | mRNA-1273 | Two-dose waned | Symptomatic disease | 14.9 | 2.9 - 24.7 | 426.3 | 500.9 |
| 56 | mRNA-1273 | Three-dose boosted | Symptomatic disease | 66.3 | 63.7 - 68.8 | 902.5 | 2678 |

References

- 1 Anichini G, Terrosi C, Gori Savellini G, Gandolfo C, Franchi F, Cusi MG. Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants. *Vaccines* 2021; **9**: 517.
- 2 Bowen JE, Addetia A, Dang HV, *et al.* Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. *Science* 2022; **377**: 890–4.
- 3 Cameroni E, Bowen JE, Rosen LE, *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* 2022; **602**: 664–70.
- 4 Cantoni D, Siracusano G, Mayora-Neto M, *et al.* Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. *Vaccines* 2022; **11**: 58.
- 5 Cele S, Jackson L, Khoury DS, *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.12.08.21267417.
- 6 Davis C, Logan N, Tyson G, *et al.* Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.06.23.21259327.
- 7 Doria-Rose NA, Shen X, Schmidt SD, *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.12.15.21267805.
- 8 Dupont L, Snell LB, Graham C, *et al.* Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. *Nat Microbiol* 2021; **6**: 1433–42.

- 9 Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, *et al.* mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 2022; **185**: 457-466.e4.
- 10 Gruell H, Vanshylla K, Tober-Lau P, *et al.* mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med* 2022; **28**: 477–80.
- 11 Hachmann NP, Miller J, Collier AY, Barouch DH. Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6. *n engl j med* 2022; : 3.
- 12 Iketani S, Liu L, Guo Y, *et al.* Antibody evasion properties of SARS-CoV-2 Omicron sublineages. *Nature* 2022; **604**: 553–6.
- 13 Leier HC, Bates TA, Lyski ZL, *et al.* Previously infected vaccinees broadly neutralize SARS-CoV-2 variants. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.04.25.21256049.
- 14 Liu Y, Liu J, Xia H, *et al.* Neutralizing Activity of BNT162b2-Elicited Serum. *The new england journal of medicine* 2021.
- 15 Lu L, Mok BWY, Chen LL, *et al.* Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. *Clinical Infectious Diseases* 2022; **75**: e822–6.
- 16 Lustig Y, Zuckerman N, Nemet I, *et al.* Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. *Eurosurveillance* 2021; **26**. DOI:10.2807/1560-7917.ES.2021.26.2100557.
- 17 Lyke KE, Atmar RL, Islas CD, *et al.* Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. *Cell Reports Medicine* 2022; **3**: 100679.
- 18 McCallum M, Bassi J, De Marco A, *et al.* SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. *Science* 2021; **373**: 648–54.
- 19 Qu P, Faraone JN, Evans JP, *et al.* Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. *n engl j med* 2022; : 3.
- 20 Su D, Li X, He C, *et al.* Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate. *bioRxiv* 2021; : 2021.05.16.444369.
- 21 Tang J, Lee Y, Ravichandran S, *et al.* Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19. *bioRxiv* 2021; : 2021.03.19.436183.

- 22 van Gils MJ, Lavell AHA, van der Straten K, *et al.* Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.09.27.21264163.
- 23 Wilhelm A, Widera M, Grikscheit K, *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.12.07.21267432.
- 24 Wu K, Werner AP, Moliva JI, *et al.* mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *Immunology*, 2021 DOI:10.1101/2021.01.25.427948.
- 25 Yu J, Collier AY, Rowe M, *et al.* Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *N Engl J Med* 2022; **386**: 1579–80.
- 26 Yu X, Wei D, Xu W, *et al.* Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. *Nature Communications* 2022; **13**: 1788.
- 27 Polinski JM, Weckstein AR, Batech M, *et al.* Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine. *Infectious Diseases (except HIV/AIDS)*, 2021 DOI:10.1101/2021.09.10.21263385.
- 28 Skowronski DM, Setayeshgar S, Febriani Y, *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medRxiv* 2021; : 2021.10.26.21265397.
- 29 Andrews N, Tessier E, Stowe J, *et al.* Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *Epidemiology*, 2021 DOI:10.1101/2021.09.15.21263583.
- 30 Stowe J, Andrews N, Gower C, *et al.* Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. 2021.
- 31 Haas EJ, Angulo FJ, McLaughlin JM, *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet* 2021; **397**: 1819–29.
- 32 Martínez-Baz I, Miqueleiz A, Casado I, *et al.* Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. *Eurosurveillance* 2021; **26**. DOI:10.2807/1560-7917.ES.2021.26.2100438.
- 33 Nasreen S, Chung H, He S, *et al.* Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *Nat Microbiol* 2022; **7**: 379–85.

- 34 Bajema KL, Dahl RM, Prill MM, *et al.* Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**: 1294–9.
- 35 Tartof SY, Slezak JM, Fischer H, *et al.* Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The Lancet* 2021; : S0140673621021838.
- 36 Bruxvoort KJ, Sy LS, Qian L, *et al.* Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. *medRxiv* 2021; : 2021.09.29.21264199.
- 37 Ranzani OT, dos Santos Leite R, Castilho LD, *et al.* Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design. *medRxiv* 2021; : 2021.10.15.21265006.
- 38 Lopez Bernal J, Andrews N, Gower C, *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; **385**: 585–94.
- 39 Heath PT, Galiza EP, Baxter DN, *et al.* Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *N Engl J Med* 2021; **385**: 1172–83.
- 40 Emary KRW, Golubchik T, Aley PK, *et al.* Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). *SSRN Journal* 2021. DOI:10.2139/ssrn.3779160.
- 41 Sadoff J, Gray G, Vandebosch A, *et al.* Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**: 2187–201.
- 42 Shinde V, Bhikha S, Hoosain Z, *et al.* Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 2021; **384**: 1899–909.
- 43 Al Kaabi N, Zhang Y, Xia S, *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA* 2021; **326**: 35.
- 44 Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* 2021; **397**: 99–111.
- 45 Tanriover MD, Doğanay HL, Akova M, *et al.* Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The Lancet* 2021; **398**: 213–22.
- 46 Jakarta WSICI. Indonesia grants emergency approval for Sinovac vaccine. The Straits Times. 2021; published online Jan 12. <https://www.straitstimes.com/asia/se-asia/indonesia-grants-emergency-approval-for-sinovac-vaccine> (accessed March 30, 2023).

- 47 Baden LR, El Sahly HM, Essink B, *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; **384**: 403–16.
- 48 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial. Novavax Investor Relations. <https://ir.novavax.com/2021-06-14-Novavax-COVID-19-Vaccine-Demonstrates-90-Overall-Efficacy-and-100-Protection-Against-Moderate-and-Severe-Disease-in-PREVENT-19-Phase-3-Trial> (accessed March 30, 2023).
- 49 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603–15.
- 50 Logunov DY, Dolzhikova IV, Shcheplyakov DV, *et al.* Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *The Lancet* 2021; **397**: 671–81.
- 51 Tang P, Hasan MR, Chemaitelly H, *et al.* BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 2021; **27**: 2136–43.
- 52 Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional Health - Europe* 2021; **11**: 100249.
- 53 Tseng HF, Ackerson BK, Luo Y, *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**: 1063–71.
- 54 Hansen C, Schelde A, Moustsen-Helm I, *et al.* Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study. *Research Square* 2022; published online March 30. DOI:10.21203/rs.3.rs-1486018/v1.
- 55 SARS-CoV-2 variants of concern and variants under investigation. 2021; published online Dec 31.
- 56 Andrews N, Stowe J, Kirsebom F, *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**: 1532–46.